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Abstract
The specific genes and genetic pathways associated with pancreatic ductal adenocarcinoma are still largely unknown
partially due to the low resolution of the techniques applied so far to their study. Here we used high-density 500 K single
nucleotide polymorphism (SNP)-arrays to define those chromosomal regions which most commonly harbour copy number
(CN) alterations and loss of heterozygozity (LOH) in a series of 20 PDAC tumors and we correlated the corresponding genetic
profiles with the most relevant clinical and histopathological features of the disease. Overall our results showed that primary
PDAC frequently display (.70%) extensive gains of chromosomes 1q, 7q, 8q and 20q, together with losses of chromosomes
1p, 9p, 12q, 17p and 18q, such chromosomal regions harboring multiple cancer- and PDAC-associated genes. Interestingly,
these alterations clustered into two distinct genetic profiles characterized by gains of the 2q14.2, 3q22.1, 5q32, 10q26.13,
10q26.3, 11q13.1, 11q13.3, 11q13.4, 16q24.1, 16q24.3, 22q13.1, 22q13.31 and 22q13.32 chromosomal regions (group 1;
n=9) versus gains at 1q21.1 and losses of the 1p36.11, 6q25.2, 9p22.1, 9p24.3, 17p13.3 and Xp22.33 chromosomal regions
(group 2; n=11). From the clinical and histopathological point of view, group 1 cases were associated with smaller and well/
moderately-differentiated grade I/II PDAC tumors, whereas and group 2 PDAC displayed a larger size and they mainly
consisted of poorly-differentiated grade III carcinomas. These findings confirm the cytogenetic complexity and heterogenity
of PDAC and provide evidence for the association between tumor cytogenetics and its histopathological features. In
addition, we also show that the altered regions identified harbor multiple cancer associate genes that deserve further
investigation to determine their relevance in the pathogenesis of PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease
with a 5-year mortality rate of almost 100%. As in other types of
cancer, understanding of the molecular mechanisms involved in
tumor development and progression is a prerequisite to improve
early diagnosis and therapy. Usage of a wide battery of techniques
such in situ fluorescence hybridization (FISH), comparative
genomic hybridization (CGH) and array-CGH (aCGH), has
allowed identification of multiple specific recurrently altered
chromosomal areas in PDAC tumors; most frequently reported
alterations include losses of chromosomes 8p, 9p, 17p and 18q,
together with gains of chromosomes 3q, 8q and 20q [1–4].
However, the identification of the specific genes targeted by such
abnormalities has proven difficult with these approaches, partially
due to the fact that these techniques have a relatively limited
resolution. In fact, the highest resolution of such approaches
applied so far to the study of PDAC are based on aCGH[5,6]
which has proven to be still relatively limited in resolution for
detailed characterization of small regions carrying genetic changes
and the identification of the involved genes.
The development of wide-genome approaches such as high-
density single nucleotide polymorphism (SNP)-arrays, has further
improved the sensitivity of aCGH and provided the opportunity
for large scale genotyping with a more accurate definition of the
magnitude of the abnormalities detected, through the identifica-
tion of copy number variation (CNV) and loss of heterozigosity
(LOH) for hundreds of thousands of SNPs[7]. This allows highly
precise mapping of those genetic changes occurring across the
entire genome in a major fraction of all tumor cells, providing a
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M     dpromising starting point for the identification of novel candidate
genes affected by such genomic alterations and profiles. To the
best of our knowledge, only Jones et al and Harada et al[8,9] have
previously applied the SNP-array technology to primary PDAC
samples and none of them has investigated so far the potential
association between SNP-array profiles of copy number alterations
and tumor histopathology.
In the present study, we applied higher density 500 K SNP arrays
with a 2.5 Kb of resolution, to a series of 20 PDAC tumors vs. paired
peripheral blood (PB) samples from an identical number of patients
who underwent complete tumor resection. Our major goal was to
map the most common reccurrent chromosomal alterations present
at diagnosis in PDAC tumors and correlate them with the
histopathological subtypes of the disease. Overall, the copy number
values (CNV) obtained confirm that primary PDAC frequently
(.70%) carry extensive gains of chromosomes 1q, 7q, 8q and 20q,
together with losses of chromosomes 1p, 9p, 12q, 17p and 18q; these
chromosomal regions, contain multiple cancer genes known to be
directly related to PDAC disease. Most interestingly, we show for the
first time the existence of two major groups of PDAC defined on the
basis of the altered SNP-array profiles which showed a close
association with tumor histopathology.
Materials and Methods
Patients and samples
Tissue specimens were obtained at diagnosis from 20 sporadic
PDAC patients (15 males and 5 females) -mean age of 67 years
(range: 45 to 84 years)-. All patients underwent surgical tumor
resection at the Division of Hepatobiliary and Pancreatic Surgery
of the University Hospital of Salamanca (Salamanca, Spain),
between October 2003 and October 2008. The study was
approved by the local ethics committee of the University Hospital
of Salamanca (Salamanca, Spain) and written informed consent
was given by each individual prior to entering the study, according
to the Helsinki Declaration.
Tumors were diagnosed and classified according to Adsay et al.[10]
with the following distribution: 5 cases corresponded to well-
differentiated/grade I tumors; 7 to moderately-differentiated/grade
II, and; 8 to poorly-differentiated/grade III PDAC. Histopathological
grade was confirmed in all cases in a second independent evaluation
by an experienced pathologist. Most tumors (18/20, 90%) were
localized in the head of the pancreas; the remaining two cases were
localized in the pancreatic body and body/tail, respectively. Mean
tumor size at diagnostic surgery was of 3.060.95 cm; 10 cases
corresponded to TNM stage IIA tumors and the other 10 to TNM
stage IIB. The most relevant clinical and laboratory patient
characteristics are summarized in table 1.
Once histopathological diagnosis had been established, part of
the tumor sample showing both macroscopical and microscopical
infiltration was used to prepare single cell suspensions for iFISH
and SNP-array studies. From the paraffin-embedded tissue
samples, sections were cut from three different areas representative
of the tumoral tissue and placed over poly L-lysine coated slides.
All tissues were evaluated after hematoxylin-eosin staining to
confirm the presence and determine the quantity of tumor cells
infiltrating the material to be studied by SNP-arrays. For SNP-
array studies, tumor DNA was extracted from freshly-frozen
tumor tissues mirror cut to those used for iFISH analyses, which
contained $70% tumor cells. In turn, normal DNA was extracted
from matched PB leucocytes from the same patient. For both types
of samples (tumor tissue and PB leucocytes), DNA was extracted
using the QIAamp DNA mini kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions.
SNP-array studies
Paired samples of purified tumoral DNA and normal PB DNA
from individual patients were hybridized to two 250 K Affymetrix
SNP Mapping arrays each (NspI and StyI SNP arrays; Affymetrix,
Santa Clara, CA, with a median resolution of 2.5 Kb and an
average distance between SNPs of 5.8 Kb), using a total of 250 ng
of DNA per array, according to the instructions of the
manufacturer. Fluorescence signals were detected using the
GeneChip Scanner 3000 (Affymetrix) and data stored in CEL
files. Analysis of paired tumoral/normal CEL files containing data
on the SNP-array results was done using the Genotyping Console
software (GTC v2.1, Affymetrix). Genotypes were generated using
the BRLMM algorithm included in the GTC software. The mean
call rate for individual SNPs was systematically $86.5% (median
of 98.6%). Copy number (CN) alterations and loss of hetero-
zigocity (LOH) were inferred by a Hidden Markov Model-based
algorithm implemented in the GTC software program, using
parameter settings recommended by Affymetrix for tumoral/
normal paired samples and a minimum physical length of at least 5
consecutive SNPs for putative genetic alterations. ‘‘Genetic gains’’
(CN$2.5) and ‘‘losses’’ (CN#1.7) were defined according to GTC
working criteria. In turn, ‘‘high CN gains’’ and ‘‘homozygous
losses’’ were considered to be present when CN values $4 and
CN#0.3 were found, respectively.
At every locus, LOH was assumed to be present when a single
allele was detected in tumor DNA from heterozygous individuals
at a greater percentage than the other allele; it was further
subclassified as either true LOH, when loci at which one of the
parental copies of a chromosome was deleted, or as copy neutral
LOH (cnLOH), when tumoral DNA displayed two copies of a
chromosomal region from one parent in the absence of the allele
derived from the other parent. Analysis of LOH was restricted to
DNA sequences from autosomal chromosomes.
Interphase fluorescence in situ hybridization (iFISH)
studies
In all cases, iFISH studies were performed on an aliquot of the
single cell suspension prepared from the tumor sample. A set of 12
locus-specific FISH probes directed against DNA sequences
localized in 11 different human chromosomes and specific for
those chromosomal regions more frequently gained or deleted in
PDAC, were systematically used to validate the results obtained
with the SNP-arrays (Table 2). The methods and procedures used
for the iFISH studies have been previously described in detail[11] .
Statistical Methods
For all continuous variables, mean values and their standard
deviation (SD) and range were calculated using the SPSS software
package (SPSS 12.0 Inc, Chicago, IL USA); for dichotomic
variables, frequencies were reported. In order to evaluate the
statistical significance of differences observed between groups, the
Mann-Whitney U and X2 tests were used for continuous and
categorical variables, respectively (SPSS). A multivariate stepwise
regression analysis (regression, SPSS) was performed to examine
the correlation between the chromosomal abnormalities found by
iFISH versus SNP-array techniques. Hierarchical clustering
analysis was performed to classify cases according to their CN
genetic profile by using the Cluster 3.0 software (PAM software;
http://www-stat.stanford.edu/,tibs/PAM). Clustering was run
using an Euclidean distance metric and the average linkage
method. For visualization of dendograms the TreeView software
1.0.4[12] was used. P-values ,.01 were considered to be
associated with statistical significance.
Genetic Profile of PDAC
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Case
ID Gender
Age
(years)
CA19.9
serum
levels
(U/ml)
Localization
of primary
tumor
Histological
grade
Tumor
size
(cm)
TNM
stage LNR
Perineural
Invasion
Vascular
Invasion
Type of
surgical
resection
Genetic
subgroup*
1F 7 4 .500 Head I 2 T3N0M0 IIA 0/17 + -R 0 1
2 M 74 144 Head I 2.5 T2N1M0 IIB 3/25 + -R 1 1
3 F 79 177 Head I 2.5 T2N1M0 IIB 3/28 + -R 0 1
4 M 64 41.4 Head I 2.2 T3N1M0 IIB 3/16 + -R 1 2
5 F 73 377 Head I 2 T3N0M0 IIA 0/10 + -R 0 2
6M 7 7 .500 Head II 3.5 T3N1M0 IIB 4/29 + -R 0 1
7M 7 3 ,2.5 Head II 2 T3N1M0 IIB 1/27 - - R0 1
8 M 61 3 Head II 3 T2N0M0 IIA 0/27 + -R 1 1
9M 5 1 .500 Head II 2.5 T3N1M0 IIB 1/18 ++ R1 1
10 M 88 89 Head II 2 T3N0M0 IIA 0/18 - - R1 1
11 M 74 45.3 Head II 3.5 T2N1M0 IIB 5/5 + -R 1 2
12 M 65 ,2.5 Head II 3 T3N1M0 IIB 2/24 + -R 0 2
13 M 60 313 Head III NA T3N0M0 IIA 0/0 + -R 0 2
14 M 74 315 Head III 4 T3N0M0 IIA 0/37 - - R0 2
15 M 56 .500 Head III 3 T3N0M0 IIA 0/32 + -R 0 1
16 F 45 .500 Head III 3.5 T2N1M0 IIB 9/72 + -R 0 2
17 M 78 176 Head III 3.5 T2N1M0 IIB 1/27 + -R 0 2
18 M 62 58 Head III 2.8 T3N0M0 IIA 0/13 + -R 0 2
19 F 76 124 Body/tail III 5.8 T2N1M0 IIB 1/16 - - R0 2
20 M 46 ,2.5 Body III 4 T3N0M0 IIA 0/18 + -R 0 2
M: male; F: female; CA19.9: carbohydrate associated antigen; LNR: lymph node ratio expressed as number of positive lymph nodes from all lymph nodes analyzed; R0:
negative microscopic resection margins. R1: positive microscopic resection margins. NA: data not available.
*as defined by hierarchical clustering analysis of CNV obtained by SNP-arrays studies.
doi:10.1371/journal.pone.0022315.t001
Table 2. Correlation between the numerical changes detected by 12 iFISH probes and CN values obtained with the SNP-arrays for
the same chromosomal regions in 20 PDAC.
FISH probe
Chromosome
localization
iFISH probe
length (kb)
N. of SNPs* inside the region
identified by the FISH probe R2 (P-value)
LSI N-MYC 2p24 200 38 0.70 (0.001)
LSI D5S23 5p15 450 118 0.60 (0.005)
LSI SEC63 6q21 275 275 0.76 (,0.001)
LSI MYB 6q23 740 88 0.56 (0.01)
LSI D7S486 7q31 200 33 0.62 (0.004)
LSI CMYC 8q24 600 159 0.79 (,0.001)
LSI PTEN 10q23 368 49 0.70 (0.001)
LSI TEL 12p13 350 98 0.76 (,0.001)
LSI LAMP1 13q34 550 92 0.55 (0.012)
LSI HER2 17q11 109 10 0.59 (0.006)
LSI BCL2 18q21 750 153 0.64 (0.002)
LSI AML1 21q22 500 111 0.60 (0.005)
All probes were purchased from Vysis Inc (Chicago, IL, USA), except for the 6q21 and 12p13, which were obtained from QBIOgene Inc (Amsterdam, The Netherlands).
R
2: Coefficient of correlation;
*Affymetrix 500 K SNP array plataform; iFISH: Interphase fluorescence in situ hybridation.
doi:10.1371/journal.pone.0022315.t002
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Frequency and type of chromosomal abnormalities
detected by SNP-arrays
Identification of chromosomal regions throughout the whole
genome of PDACs with CN alterations and LOH showed that
those chromosomal regions most frequently lost were 17p12 (15/
20 cases; 75%), followed by 1p35, 9p22, 12q23 and 18q21 (14/20
cases; 70%) (Table 3). Similarly, gains were frequently observed at
chromosomes 1q21.2 and 8q24.3 (15/20 cases; 75%), followed by
chromosomes 7q36 and 20q13 (14/20 cases; 70%). Gains and
losses of many other chromosomal regions were identified at lower
frequencies (#65%; Table S1).
In adittion, large chromosomal regions displaying LOH were
also detected in most PDAC tumors (80% of cases) at
chromosomes 17p13.1–17p11.2 (7.5 Mb) and 17p13.3–17p13.1
(6.9 Mb) (Table 3). Noteworthy, the latter region showed complex
patterns of genetic changes including LOH (10/20 cases; 50%),
cnLOH (3/20 cases, 15%) and cnLOH associated with total or
partial CN gains (3/20 cases, 15%). Additional LOH regions were
identified on chromosome 9p (n=8 regions that expanded from
9p21.1 to the 9p24.1 chromosome band), and chromosome 18q
(n=4 regions at 18q12.1–18q12.3 and another 2 regions in
18q21.1 and 18q22.1–18q22.2, respectively). Interestingly, LOH
at chromosome 9p mainly involved regions associated with
deletions of one copy of specific chromosomal areas, while LOH
at chromosome 18q displayed more complex patterns of LOH in
association with cnLOH.
Correlation between the chromosomal changes detected
by SNP-arrays and iFISH
Overall our results showed a high degree of correlation
between the SNP-array and iFISH results with a mean R2 of
0.656008 (range: 0.55 to 0.79) between both methods (Table 2).
In addition, chromosomal abnormalities identified in those
chromosomal regions evaluated by iFISH were similar to those
found by SNP-array studies: gains/amplifications at 2p24 were
detected in 30% of the cases by iFISH versus 20% by SNP-
arrays studies (R2=0.70; p,0.001) as well as at 5q31 found in
25% of cases by iFISH vs. 30% by SNP-arrays studies (R2=0.60;
p,0.005) and 8q34 (55% Vs. 50%; R2=0.79; p,0.001); similarly,
gains/amplifications and deletions of 7q31 (20%and 20% vs. 5% and
10%, respectively; R2=0.62; p,0.004), 10q23 (10% and 20% vs.
5% and 10%; R2=0.70; p,0.001), 12p13 (20% and 45% vs. 15%
and 25%; R2=0.76; p,0.001), 13q34 (25% and 15% vs. 55% and
10%; R2=0.55; p,0.012), 17q11 (15% and 10% vs. 25% and 20%;
R2=0.59; p,0.006); similarly, deletions of chromosomes 6q21 (50%
vs. 40%, respectively; R2=0.76; p,0.001), 6q23 (35% vs. 40%;
R2=0.56; p,0.01), 18q21 (75% vs. 49%; R2=0.64; p,0.002) and
21q22 (45% vs. 40%; R2=0.60; p=0.005), were detected at similar
frequencies with both methods.
Cancer-associated genes coded in chromosomal regions
frequently altered in PDAC
By integrating the genomic public data (Ensembl relase 59,
Human build GRCh37) with our CN and LOH results, we
sought to identify regions which showed recurrent CN changes
containing at least one known and well-characterized gene
(Table 4). Accordingly, CN gains were frequently detected
($75%) in those chromosomal regions coding for the PSCA,
S L U R P 1 ,N T S R 1 ,C D H 4 ,B A I 1 ,T A R S 2 ,G M L ,O G F Rand
PTPRN2 genes, which have been described to be involved in
cancer and/or pancreatic functions. Remarkably, from these
genes, the PSCA, NTSR1, OGFR and TNFRSF6B genes have
also been associated with pancreatic malignancies and the sonic
hedgehog gene has been directly related to stem-cellness. In turn,
the most commonly deleted gene was MYOCD, a cancer related
gene which also displayed LOH in most of our cases (80%;
Table 3); other frequently deleted cancer-associated genes
included the E Y A 3 ,N R 2 C 1 ,P T A F R , and the DCC cancer
associated genes which have also been involved in pancreatic
cancer. In turn, common regions of LOH also included two
genes that have been involved in pancreatic cancer: the RPH3AL
and SERPINF1 genes at chromosome 17p13. Noteworthy,
regions of LOH identified in chromosome 18q12 also contain
genes that have been reported to be involved in pancreatic
malignant tumors, e.g. the MAPRE2 gene found to be deleted by
LOH in 50% of the cases and by cnLOH in another 20% of the
tumors. Other cancer-associated genes coded in those chromo-
somal regions displaying LOH in a relatively high proportion of
cases are listed in Table 3.
Association between the CNV and LOH profile of PDAC
tumors and other disease characteristics
Univariate analysis revealed a significant association between
gains of the 10q26.13–q26.3, 11q13.1–q13.4 and 22q13.1–q13.32
chromosomal regions and grade I/II tumors (p#0.03). Similarly, a
significant association was found between cases with gains at the
10q26.13, 10q26.3, 11q13.1and 22q13.1–q13.32 chromosomal
regions and smaller tumor sizes (average tumor size of 2.5 cm vs.
3.4 cm; p#0.04), whereas Xp22.33 losses were associated with
larger tumors (median tumor size of 3.5 cm vs. 2.6 cm; p=0.03)
(Table S2). No other significant associations were found between
specific genetic changes and other disease features (gender, age,
CA19.9 serum levels, localization of primary tumor, TNM stage,
LNR, perineural invasion, vascular invasion and type of surgical
resection).
Hierarchical clustering analysis of the 20 PDAC tumors
studied according to their CNV and LOH profiles showed the
existence of two well-defined groups of tumors (Figure 1). All 9
PDAC tumors from group 1 showed gains of the 2q14.2, 3q22.1,
5q32, 10q26.13, 10q26.3, 11q13.1, 11q13.3, 11q13.4, 16q24.1,
16q24.3, 22q13.1, 22q13.31 and 22q13.32 chromosomal re-
gions, while group 2 consisted of 11 cases who shared gains of
the 1q21.1 chromosomal region together with a relatively high
frequency of losses ($64% of cases) of the 1p36.11, 6q25.2,
9p22.1, 9p24.3, 17p13.3 and for Xp22.33 chromosomal regions.
Interestingly, the former group also showed a high rate of well/
moderate-differentiated grade I/II PDAC tumors (8/9 cases,
89%; p=0.03), while group 2 patients mainly corresponded to
poorly-differentiated, grade III carcinomas (8/11 cases, 73%;
p=0.03) (Figure 1). Twelve cancer-associated genes mapping in
six of these regions were identified to be altered: the INPP5A (at
10q26.3), CDX1, CAMK2A (at 5q32), MB and APOL6 (both at
22q13.1) genes among the former (group 1) cases, and the
SFRS13A (1p36.11), VPS53, FAM57A, GEMIN4, ELP2P and
GLOD4 (all of them at 17p13.3) and the CSF2RA and the IL3RA
(both at Xp22.33) genes, all deleted among group 2 cases
(Figure 1) .
Discussion
PDAC are heterogeneous tumors that frequently display
complex genetic profiles as confirmed in the present study
where multiple CNV and LOH regions were identified in every
case analyzed. Overall, our findings indicate that the genetic
profile of primary PDAC is defined by imbalanced losses of
Genetic Profile of PDAC
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Chromosomal (Chr) region (bp)
Chromosome
band Length (Kb)
N. of SNPs in
the altered
region
%o f
altered
cases Genes involved* (N. of genes)
CN Losses
chr1: 28,370,650–28,562,758 p35.3 192 16 70% EYA3, PTAFR (3)
chr9: 14,980,485–15,038,399 p22.3 57.9 10 70% (1)
chr12: 95,450,296–95,526,343 q23.1 76 16 70% NR2C1 (2)
chr17: 2,981,856–3,082,150 p13.3 100 23 70% (2)
9,200,905–9,347,984 p13.1 347 38 70% (1)
11,246,600–11,347,984 p12 101 36 75% (1)
12,306,804–12,540,753 p12 234 44 75% MYOCD (2)
47,053,989–47,085,681 q21.1 31.7 9 70% (0)
47,095,478–47,133,926 q21.1 38.5 11 70% (1)
chr18: 50,371,940–50,528,205 q21.2 156 29 70% DCC (1)
53,612,861–53,710,464 q21.31 97.6 26 70% (1)
CN Gains
chr1: 147,306,690–147,521,567 q21.2 214.9 8 75% (6)
150,306,335–150,329,391 q21.3 23 5 70% PRPF3 (1)
150,355,573–150,496,340 q21.3 140.8 30 70% TARS2, ECM1 (5)
chr7: 154,876,017–154,924,521 q36.3 48.5 18 70% (1)
155,386,030–155,490,447 q36.3 104 22 70% (1)
157,638,633–157,783,490 q36.3 91 20 70% PTPRN2 (1)
chr8: 142,428,444–142,726,810 q24.3 298 46 70% PTP4A3 (3)
142,754,129–143,356,971 q24.3 602.8 99 75% (2)
143,374,709–143,377,003 q24.3 2.3 5 70% (1)
143,564,928–143,854,26 q24.3 289 30 70% BAI1, PSCA, SLURP1 (20)
143,899,694–143,999,285 q24.3 99.6 20 75% GML (3)
chr20: 55,633,244–55,734,303 q13.32 101 26 70% (2)
55,744,225–55,754,966 q13.32 10.7 10 70% BMP7 (1)
59,550,109–59,777,020 q13.33 226.9 49 70% (1)
59,785,516–59,832,199 q13.33 46.7 8 70% CDH4 (1)
61,160,156–61,505,547 q13.33 345 32 70% NTSR1, OGFR (15)
62,246,579–62,376,958 q13.33 130 24 70% STMN3, RTEL1, ZGAPT, SLC2A4RG,
ARFRP1, TNFRSF6B
(9)
LOH
chr9: 7,641,255–9,061,636 p24.1–p23 1420.4 433 75% PTPRD1 (2)
9,415,137–17,868,117 p23–p22.2 8453 2138 75% PTPRD1, TYRP1, NFIB, ZDHHC21, CER1,
PSIP1, BNC2, SH3GL2
(16)
19,032,340–20,480,069 p22.1–p21.3 1447.7 290 75% PLIN2, RPS6, MLLT3 (9)
21,060,888–21,143,835 p21.3 82.9 25 75% (2)
21,370,303–21,505,928 p21.3 135.6 19 75% (5)
22,902,094–23,164,592 p21.3 262.5 37 75% (0)
25,043,325–27,458,065 p21.3–p21.2 2414.7 539 75% TUSC1,TEK, NCRNA00032 (9)
30,978,599–31,917,398 p21.1 938.8 190 70% (0)
chr17: 0–6,858,022 p13.3–p13.1 6858 988 80% RPH3AL, FAM57A, GEMIN4, YWHAE, CRK,
SERPINF2, SERPINF1, SMYD4, RPA1, HIC1,
MNT, TM4SF5, NUP88, XAF1SMYD4, RPA1,
HIC1, MNT, P2RX5, CAMKK1, ATP2A3,
CYB5D2, MYBBP1A, ALOX15, PELP1,
TM4SF5, PLD2, SLC25A11, RNF167, PFN1,
USP6, NUP88, DHX33, XAF1, ALOX12
(132)
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the 1q, 7q, 8q and 20q chromosomal regions. These results
confirm previous analyses using chromosome banding tech-
niques[13,14], CGH[15], aCGH[1,2,4,16], low-resolution 100K
SNP-arrays[8] and gene sequencing combined or not with SNP-
array technology [9,17]. Despite a high correlation was also
found between the SNP-array results and iFISH analyses
performed on the same series of primary tumors samples - as
regards the most commonly deleted (e.g. 17p, 18q, 9p and 8p)
and gained (e.g. 1q, 15q and 8q) chromosomal regions[11]-, a
higher frequency of deletions at chromosomes 1p and 17q, and
gains at chromosomes 7q and 20q were found by SNP- arrays vs.
iFISH technique (around 70–75% vs. 5–25%, respectively). Such
discrepancies could be explained, at least in part, by the
increased sensitivity of the SNP-array vs. iFISH studies in the
identification of small interstitial changes[18].
A more detailed analysis of the most frequently altered
chromosomal regions shows that they contain multiple cancer-
associated genes, including several genes which have been
specifically related to PDAC. Among others, these latter genes
consisted of gained genes such as the PSCA gene, a plausible
PDAC tumor marker associated with pancreatic cancer progres-
sion[19–22], the TNFRSF6B gene (a member of the tumor
necrosis factor receptor family) which is amplificated in many
tumors [23–26] and whose overexpression blocks growth
inhibition signals in PDAC[27], and the NTSR1 and OGFR
genes, involved in cancer progression[28–30], modulation of
angiogenesis[31] and regulation of cell proliferation[32]. In turn,
frequently deleted genes of interest were the RPH3AL gene, a
potential tumor suppressor gene related with insulin exocyto-
sis[33], the SERPINF1 gene which has been detected to be
involved in many epithelium derived tumors[34,35], and the
MAPRE2 gene, previously found to be lost in leukemic cells[36],
pancreatic cancer[37] and esophageal squamous cell carcino-
ma[38]; interestingly, deletion of other cancer associated genes
which have not been previously associated to pancreatic
malignances (MYOCD[39,40], NR2C1[41] and PTAFR[42]) were
found at higher frequencies than other (e.g. CDKN2A, TP53 or
SMAD4[43,44]) genes shown to be recurrently altered/deleted in
PDAC. These results underline the potential role of several
previously unexplored tumor suppressor genes in the pathogen-
esis of PDAC. In turn, genes which have been previously found
to be amplified in PDAC patients by SNP-arrays[8], such as the
SACP2 gene, were also altered in our series but at a lower
frequency (e.g. 60% vs. 40% of cases, respectively). Such
variability could be partially related to the lower number of
patients analyzed and the effect of studying paired tumoral/
normal DNA samples in the resolution of the SNP-array for
detection of CN alterations.
Most interestingly, is the observation that based on the overall
genetic profile of PDAC tumors detected by SNP-arrays two well
defined groups of PDAC tumors emerge which are differentially
characterized by gains of the 2q14.2, 3q22.1, 5q32, 10q26.13,
10q26.3, 11q13.1, 11q13.3, 11q13.4, 16q24.1, 16q24.3,
22q13.1, 22q13.31 and 22q13.32 chromosomal regions (group
1) and by gains at 1q21.1 with coexisting losses of the 1p36.11,
6q25.2, 9p22.1, 9p24.3, 17p13.3 and Xp22.33 chromosomal
regions (group 2), respectively. From the clinical and histopatho-
logicall point of view, while group 1 PDAC mostly corresponded
to smaller well/moderately differentiated grade I/II cases, group
2 mainly consisted of larger and poorly-differentiated PDAC.
Among the few well/moderately differentiated carcinomas
included in this latter group, 2/3 cases showed intermediate
cytogenetic features with coexistence of gains of chromosomes
1q21.1 together with gains of chromosomes 10q, 22q and 11q.
Whether these two distinct cytogenetic profiles reflect different
cytogenetic pathways vs. sequential stages of development of
P D A C ,r e m a i n st ob ed e t e r m i n e d .H o w e v e r ,t h ei d e n t i f i c a t i o no f
rather different and non-overlapping chromosomal changes in
both groups of tumors would support they could more likely
reflect two genetically different diseases. Further studies in larger
series of patients are warranted to elucidate this question and
determine the specific role of those cancer associated genes
(INPP5A, CDX1, MB, CAMK2A, APOL6 vs. VPS53, FAM57A,
GEMIN4, SFRS13, ELP2P, GLOD4, CSF2RA and IL3RA),
differentially altered in both groups of tumors. In this regard,
it should be noted that from those genes, two or more are
involved in common intracellular pathways such the cytokine-
cytokine receptor interactions involving Jak-STAT signaling
(IL3RA and CSF2RA genes) or RNA processing pathways
(GEMIN4 and SFRS13A genes) [45,46]. Further analyses of gene
expression profiles may contribute to determine their relevance
in the pathogenesis of PDAC.
In summary, in the present study we confirm the cytogenetic
complexity and heterogenity of PDAC and provide evidence for
the association between tumor cytogenetics and its histopatholog-
ical features. In addition, we also show that the most frequently
altered regions identified harbor multiple cancer-associated genes
that deserve further investigation to determine their relevance in
the pathogenesis of PDAC.
Chromosomal (Chr) region (bp)
Chromosome
band Length (Kb)
N. of SNPs in
the altered
region
%o f
altered
cases Genes involved* (N. of genes)
9,849,290–17,282,737 p13.1–p11.2 7433.5 1343 80% MYH1, MYH3, MAP2K4, MYOCD, NCOR1,
ZNF624, TNFRSF13B, MPRIP, FLCN
(57)
chr18: 28,634,894–29,240,123 q12.1 605 78 70% (1)
29,328,366–31,452,672 q12.1–q12.2 2124 147 70% MAPRE2 (10)
33,893,503–36,183,722 q12.2–q12.3 2290 415 75% (1)
36,600,581–40,107,505 q12.3 3506.9 657 75% PIK3C3 (4)
41,807,620–42,006,021 q21.1 198.4 18 75% (3)
61,651,678–66,668,993 q22.1–q22.2 5017 1036 70% CDH19, SOCS6 (9)
*Only cancer-associated genes (in bold) or genes related to pancreas (underlined) are shown.
doi:10.1371/journal.pone.0022315.t003
Table 3. Cont.
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CN gene alteration
Gene Coded name
Chromosomal
localization Gains
High
Copy
Gain
Total
Gains
Heterozygous
deletion
Homozygous
deletion
Prostate stem cell antigen PSCA 8q24.2 45% 35% 80% 0% 0% 0%
Secreted LY6/PLAUR domain containing 1 SLURP1 8q24.3 45% 35% 80% 0% 0% 0%
Neurotensin receptor 1 NTSR1 20q13 45% 35% 80% 0% 0% 0%
Cadherin 4, type 1, R-cadherin CDH4 20q13.3 40% 35% 75% 0% 0% 0%
Brain-specific angiogenesis inhibitor 1 BAI1 8q24 40% 35% 75% 0% 0% 0%
Threonyl-tRNA synthetase 2, mitochondrial TARS2 1q21.3 60% 15% 75% 0% 0% 0%
Glycosylphosphatidylinositol anchored molecule like
protein
GML 8q24.3 50% 25% 75% 0% 0% 0%
Opioid growth factor receptor OGFR 20q13.33 40% 35% 75% 0% 0% 0%
Protein tyrosine phosphatase, receptor type, N
polypeptide 2
PTPRN2 7q36 35% 35% 70% 10% 0% 10%
Bone morphogenetic protein 7 BMP7 3q42 65% 5% 70% 0% 0% 0%
PRP3 pre-mRNA processing factor 3 homolog PRPF3 1q21.1 60% 10% 70% 0% 0% 0%
Extracellular matrix protein 1 ECM1 1q21 55% 15% 70% 0% 0% 0%
Protein tyrosine phosphatase type IVA, member 3 PTP4A3 8q24.3 50% 20% 70% 0% 0% 0%
Stathmin-like 3 STMN3 3q43 35% 35% 70% 5% 0% 5%
Regulator of telomere elongation helicase 1 RTEL1 20q13.3 35% 35% 70% 5% 0% 5%
Zinc finger, CCCH-type with G patch domain ZGPAT 20q13.3 35% 35% 70% 5% 0% 5%
SLC2A4 regulator SLC2A4RG 20q13.33 35% 35% 70% 5% 0% 5%
ADP-ribosylation factor related protein 1 ARFRP1 20q13.3 35% 35% 70% 5% 0% 5%
Tumor necrosis factor receptor superfamily, member
6b, decoy
TNFRSF6B 20q13.3 35% 35% 70% 5% 0% 5%
Dipeptidyl-peptidase 6 DPP6 7q36.2 50% 10% 60% 10% 0% 10%
Sonic hedgehog SHH 7q36 60% 0% 60% 0% 0% 0%
Laminin, alpha 5 LAMA5 20q13.2–q13.3 40% 20% 60% 0% 0% 0%
Insulin-like growth factor 1 receptor IGF1R 15q26.3 30% 25% 55% 0% 0% 0%
Baculoviral IAP repeat-containing 7 BIRC7 20q13.3 15% 40% 55% 5% 0% 5%
Endosulfine alpha ENSA 1q21.3 55% 0% 55% 0% 0% 0%
Epidermal growth factor receptor EGFR 7p12 25% 25% 50% 0% 0% 0%
Myocardin MYOCD 17p11.2 0% 0% 0% 75% 0% 75%
Eyes absent homolog 3 EYA3 1p36 0% 0% 0% 70% 0% 70%
Nuclear receptor subfamily 2, group C, member 1 NR2C1 12q22 0% 0% 0% 70% 0% 70%
Platelet-activating factor receptor PTAFR 1p35–p34.3 0% 0% 0% 70% 0% 70%
Deleted in colorectal carcinoma DCC 18q21.3 0% 0% 0% 70% 0% 70%
Myeloid/lymphoid or mixed-lineage leukemia;
translocated to, 3
MLLT3 9p22 0% 0% 0% 60% 5% 65%
Cadherin 7, type 2 CDH7 18q22.1 0% 0% 0% 65% 0% 65%
Basonuclin 2 BNC2 9p22.2 0% 0% 0% 60% 0% 60%
Cyclin-dependent kinase inhibitor 2A CDKN2A 9p21 0% 0% 0% 55% 5% 60%
Cadherin 19, type 2 CDH19 18q22.1 0% 0% 0% 60% 0% 60%
Replication protein A1, 70kDa RPA1 17p13.3 0% 0% 0% 55% 0% 55%
TEK tyrosine kinase, endothelial TEK 9p21 0% 0% 0% 50% 5% 55%
Phosphoinositide-3-kinase, class 3 PIK3C3 18q12.3 0% 0% 0% 55% 0% 55%
doi:10.1371/journal.pone.0022315.t004
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